Can't see why the global expansion strategy won't succeed, particularly since Tony Radford, board member, has done this sort of thing before with Cellestis. Anyhow, not long to wait now - 2020 looks like exciting year.
Even just one major contract for the STI test will be huge boost as the market here is so large (page 8) with most tests done for screening purposes.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.020(4.76%) |
Mkt cap ! $90.85M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.0¢ | 40.0¢ | $25.93K | 64.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10061 | 2 |
View Market Depth
| Last trade - 11.01am 22/07/2025 (20 minute delay) ? |
| GSS (ASX) Chart |